Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nitric oxide (NO), a mediator of cardiovascular homeostasis, neurotransmission, and immune function, has recently been found to have important effects in bone. Both constitutive and inducible forms of
NO synthase
are expressed by bone-derived cells, and cytokines such as interleukin-1 (IL-1), tumor necrosis factor (TNF), and interferon gamma (IFN-gamma), are potent stimulators of NO production. When combined with other cytokines, IFN-gamma markedly induces NO production, which suppresses osteoclast formation and activity of mature osteoclasts. This "superinduction" of NO is largely responsible for the selective inhibitory effect of IFN-gamma on cytokine-induced bone resorption. High concentrations of NO are also inhibitory for cells of the osteoblast lineage, and NO production appears to be partly responsible for the inhibitory effects of cytokines on osteoblast proliferation. At lower concentrations, however, NO has different effects. Moderate induction of NO potentiates bone resorption, and the constitutive production of NO at low concentrations promotes the proliferation of osteoblast-like cells and modulates osteoblast function. NO therefore appears to be an important regulatory molecule in bone with effects on cells of the osteoblast and osteoclast lineage and represents one of the molecules produced by osteoblasts which directly regulate osteoclastic activity. Stimulation of NO production in bone by proinflammatory cytokines raises the possibility that NO may be involved as a mediator of bone disease in conditions associated with cytokine activation, such as rheumatoid arthritis,
tumor
associated osteolysis, and postmenopausal osteoporosis.
...
PMID:Nitric oxide and bone. 885 40
Adhesion of circulating
tumor
cells to microvascular endothelium plays an important role in
tumor
metastasis to distant organs. The purpose of this study was to determine whether nitric oxide (NO) would attenuate
tumor
cell adhesion (TCA) to naive or lipopolysaccharide (LPS)-treated postcapillary venules. A melanoma cell line, RPMI 1846, was shown to be much more adhesive to postcapillary venules isolated from rat mesentery than to corresponding precapillary arterioles. Although venules exposed to LPS for 4 h demonstrated an increased adhesivity for the melanoma cells, TCA to LPS-treated arterioles was not altered. Isolated venules exposed to DETA/NO (1 mM), an NO donor, for 30 min prior to
tumor
cell perfusion prevented the increment in adhesion induced by LPS and attenuated TCA to naive postcapillary venules. While L-arginine (100 microM), an NO precursor, failed to decrease TCA to naive postcapillary venules, this treatment abolished LPS-stimulated TCA to postcapillary venules. The effect of L-arginine was reversed by administration of N(omega)-nitro-L-arginine methyl ester (L-NAME, 100 microM), an
NO synthase
(
NOS
) inhibitor. These observations indicate that both exogenous and endogenous NO modulate TCA to postcapillary venules. To assess the role of NO-induced activation of cGMP in the reduction in TCA produced by DETA/NO, two additional series of experiments were conducted. In the first series, LY-83583 (10 microM), a guanylyl cyclase inhibitor, was shown to completely reverse the effect of DETA/NO on TCA to both naive and LPS-activated postcapillary venules. On the other hand, administration of 8-bromoguanosine 3',5'-cyclic monophosphate (8-B-cGMP) (1 mM), a cell permeant cGMP analog, mimicked the effect of DETA/NO and reduced TCA to LPS-stimulated postcapillary venules. These data suggest that (a)
tumor
cells are more likely to adhere to postcapillary venules than to corresponding precapillary arterioles, (b) LPS enhances TCA to postcapillary venules, (c) both exogenously applied (DETA/NO) and endogenously generated (L-arginine) NO attenuate the enhanced adhesion induced by LPS, but only DETA/NO reduced TCA to naive postcapillary venules, and (d) the NO-induced reduction in TCA to LPS-activated postcapillary venules occurs by a cGMP-dependent mechanism.
...
PMID:Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules. 887 7
We examined the effect of a nitric oxide (NO) quencher, stroma-free human hemoglobin A (HbA0; 0.01, 0.05, 0.1, 0.2 g/kg), on the blood flow measured using the Doppler flow technique,
tumor
oxygen pressure (pO2) and the diameter of the arterioles using R3230Ac mammary adenocarcinoma as the
tumor
model. In female Fischer 344 rats with 1-cm-diameter tumors implanted in the lateral aspect of the left quadriceps, intravenous infusion of 0.1 and 0.2 g/kg HbA0 decreased both central
tumor
and peripheral
tumor
blood flow by 20-30% (P < 0.05).
Tumor
pO2 decreased 28% with 0.2 g/kg HbA0, from 15 mm Hg (baseline) to 11 mm Hg at 10 min (P = 0.02). Although 0.2 g/kg HbA0 increased blood flow 55% in the left quadriceps muscle proximal to the implanted
tumor
(P < 0.05), HbA0 had little effect on blood flow in right quadriceps muscle with no
tumor
implanted, and increased right quadriceps pO2, from 21 mm Hg (baseline) to 23 mm Hg at 10 min (P = 0.03). HbA0 increased mean arterial pressure 5-10% in a manner that was dependent on dose while heart rate concurrently decreased 9-19%. The diameter of the arterioles supplying the
tumor
was rapidly reduced 10% by 0.2 g/kg HbA0 (P = 0.037) and remained stable through 60 min of observation (P = 0.005). HbA0 selectively reduces
tumor
blood flow and
tumor
pO2 through vasoconstriction of the arterioles supplying the
tumor
. Vascular NO quenching provides an alternative to
NO synthase
inhibition as a means to achieve the goal of selective
tumor
hypoxia.
...
PMID:Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. 900 11
Activated macrophages have been shown to exert cytostatic and cytotoxic effects toward
tumor
cells via nitric oxide (NO) release. In the CNS, microglial cells are considered to be the main resident population of immune effector cells. In this study, cytotoxic activity of N11, an immortalized murine microglial cell line, toward rat progressive DHD/PROb and regressive DHD/REGb colon carcinoma cells was examined in parallel with NO production. Cytotoxicity was evaluated using a novel method, the gamma-glutamyl transpeptidase (gamma-GTP) assay, based on the fact that DHD
tumor
cells expressed high levels of gamma-GTP activity, while no gamma-GTP activity was found in cells of the monocyte/macrophage lineage. Results showed that activation of N11 cells by interferon-gamma plus either lipopolysaccharide or tumor necrosis factor-alpha induced high amounts of NO release and cytotoxic effects toward DHD/PROb as well as DHD/REGb cells. NO release by activated N11 cells was augmented by addition of
tumor
cell-conditioned medium. Both NO release by N11 cells and cytotoxicity were blocked by addition of N(G)-monomethyl-L-arginine (L-NMA), an inhibitor of
NO synthase
, suggesting that cytotoxicity was mediated by N11-derived NO. However, in the presence of L-NMA an increased production of interleukin-6 was also observed. In conclusion, in opposition to information obtained with brain-derived endothelial cells, brain-derived microglial cells did not differentiate between progressive and regressive clones of colon carcinoma cells. Our results point to a specific role for both endothelial and microglial cell types in the context of brain metastasis. Microglial cells can be cytotoxic for
tumor
cells, and this cytotoxicity is mediated by NO.
...
PMID:Microglial cells induce cytotoxic effects toward colon carcinoma cells: measurement of tumor cytotoxicity with a gamma-glutamyl transpeptidase assay. 900 56
The present study was designed to define the role of nitric oxide (NO) in
tumor
microcirculation, through the direct intravital microcirculatory observations after administration of
NO synthase
(
NOS
) inhibitor and NO donor both regionally and systemically. More specifically, we tested the following hypotheses: 1) endogenous NO derived from
tumor
vascular endothelium and/or
tumor
cells increases and/or maintains
tumor
blood flow, decreases leukocyte-endothelial interactions, and increases vascular permeability, 2) exogenous NO can increase
tumor
blood flow via vessel dilatation and decrease leukocyte-endothelial interactions, and 3) NO production and tissue responses to NO are
tumor
dependent. To this end, a murine mammary adenocarcinoma (MCaIV) and a human colon adenocarcinoma (LS174T) were implanted in the dorsal skinfold chamber in C3H and severe combined immunodeficient mice, respectively, and observed by means of intravital fluorescence microscopy. Both regional and systemic inhibition of endogenous NO by N omega-nitro-L-arginine methyl ester (L-NAME; 100 mumol/L superfusion or 10 mg/kg intravenously) significantly decreased vessel diameter and local blood flow rate. The diameter change was dominant on the arteriolar side. Superfusion of NO donor (spermine NO, 100 mumol/L) increased
tumor
vessel diameter and flow rate, whereas systemic injection of spermine NO (2.62 mg/kg) had no significant effect on these parameters. Rolling and stable adhesion of leukocytes were significantly increased by intravenous injection of L-NAME. In untreated animals, both MCaIV and LS174T
tumor
vessels were leaky to albumin. Systemic NO inhibition significantly attenuated
tumor
vascular permeability of MCaIV but not of LS174T
tumor
. Immunohistochemical studies, using polyclonal antibodies to endothelial
NOS
and inducible
NOS
, revealed a diffuse pattern of positive labeling in both MCaIV and LS174T tumors. Nitrite and nitrate levels in
tumor
interstitial fluid of MCaIV but not of LS174T were significantly higher than that in normal subcutaneous interstitial fluid. These results support our hypotheses regarding the microcirculatory response to NO in tumors. Modulation of NO level in tumors is a potential strategy for altering
tumor
hemodynamics and thus improving oxygen, drug, gene vector, and effector cell delivery to solid tumors.
...
PMID:Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. 903 84
Nitric oxide (NO) is an important bioregulatory mediator involved in a variety of biological processes under both physiological and pathological conditions. To assess whether NO production is altered in colon carcinogenesis, the expression levels and localization of two isoforms of
NO synthase
, inducible
NO synthase
(iNOS) and endothelial constitutive
NO synthase
(eNOS), were examined by immunoblot and immunohistochemical methods in normal colonic mucosa and colon carcinomas induced by azoxymethane in male F344 rats. All colon carcinoma tissues examined were found to have an increased expression of iNOS and eNOS proteins as compared to normal colonic mucosa. In particular, the pronounced staining of iNOS protein localized to the luminal surface of carcinoma epithelial cells was not detectable in normal colon epithelium. The neovasculature in
tumor
tissues also demonstrated intense eNOS immunoreactivity in endothelial cells. These findings indicate that NO production is markedly elevated in azoxymethane-induced rat colon carcinomas, suggesting that regulatory pathways involving this mediator have some biological relevance to colon carcinogenesis in this model.
...
PMID:Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. 910 4
We have previously shown that 1) neutrophils activated with various cytokines, including rat recombinant interferon gamma (rIFN-gamma), inhibit
tumor
cell growth and that 2) nitric oxide (NO) is the effector molecule in
tumor
inhibition by rIFN-gamma-stimulated rat peritoneal exudate neutrophils. In this study, we examined the nature of
tumor
cell death induced by rat peritoneal neutrophils activated by rIFN-gamma in order to clarify the mechanism of apoptosis in neoplastic
tumor
cell death. DNA of 3 syngeneic rat
tumor
cell lines was significantly fragmented within 3 hr of incubation in the presence of rIFN-gamma-activated neutrophils, and this effect was dependent on both the concentration of rIFN-gamma and the number of neutrophils. This DNA fragmentation was inhibited by L-N-(I-iminoethyl)-ornithine (L-NIO), a
NO synthase
inhibitor, but not by superoxide dismutase (SOD).
Tumor
cells treated with the activated neutrophils were shown by electron microscopy to be apoptotic, exhibiting necrotic features with a longer incubation. On the other hand, cytolysis of
tumor
cells, as determined by a [3H]-uridine release assay, was first observed only at 24 hr of incubation with the rIFN- gamma-activated neutrophils. Taken together, our results suggest that
tumor
cell apoptosis by activated neutrophils is NO-dependent and that apoptotic
tumor
cells undergo necrosis as a secondary process. We suggest that
tumor
cell apoptosis induced by activated neutrophils plays an important role in regulation of neoplastic
tumor
cell growth and death in vivo.
...
PMID:rIFN-gamma-activated rat neutrophils induce tumor cell apoptosis by nitric oxide. 913 48
The aim of this study is to investigate the effect of certain polychlorinated pesticides on the induction of rat liver Ca(2+)-independent nitric oxide synthase (NOS) and compare it with the effect of bacterial lipopolysaccharide. Our results show that endosulfan and p, p'-DDT treatment significantly increases the NOS activity while no significant induction by any route of administration was observed in the case of chlordane. Our results show therefore that a wide variety of chlorinated pesticides, which are considered as hepatic
tumor
promotors, can stimulate the expression of
NO synthase
in vivo.
...
PMID:Induction of nitric oxide synthase by chlorinated pesticides (p,p'-DDT, chlordane, endosulfan) in rat liver. 916 60
Breast cancer is characterized by its ability to metastasize rapidly. Factors that might facilitate this metastatic potential include
tumor
vascularity. Nitric oxide (NO), a labile compound synthesized by
NO synthase
(
NOS
), is a major regulator not only of physiologic vascular tone but also of the abnormal vascularity associated with many tumors. To test whether
NOS
is expressed in primary breast tumors and whether its expression is associated with the presence of metastasis, we analyzed the expression of the inducible
NOS
in 22 primary breast tumors, and to investigate its association to other gene products related to the metastatic ability of
tumor
cells, we correlated the expression of the inducible
NOS
with the expression of the nm23 protein (the product of the putative antimetastatic gene nm23). We found a very strong correlation between the presence of
NOS
and axillary lymph node metastasis and between
NOS
and the absence of nm23 protein. These data suggest that NO synthesis and the resulting increase in blood flow to the
tumor
play a role in the facilitation of
tumor
metastasis.
...
PMID:Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. 923 72
Human fibrosarcoma HT1080 cell surface phenotype analysis revealed the expression of "cluster of differentiation 15" (CD15) antigen and to a lesser extent, of "very late antigen-4" (VLA-4). Expression of "endothelial-leukocyte adhesion molecule-1" (ELAM-1) was negligible on resting human umbilical vascular endothelial cells (HUVECs), but its expression could be induced by HT1080 conditioned medium. HT1080 cell adhesion to HUVECs was partially dependent on CD15/ELAM-1 adhesion molecules. HT1080 cell adhesion to HUVECs induced the enhancement of nitric oxide (NO) production from HUVECs. Exogenous NO and NO from HUVECs enhanced ELAM-1 expression on HUVECs, HT1080 cell adhesion to HUVECs, permeability of the HUVEC monolayer, and HT1080 cell invasion through the HUVEC monolayer. These enhancements were not induced by
NO synthase
inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME). These results suggest that NO expression induced by
tumor
cells via the CD15/ELAM-1 adhesion system may contribute to enhancement of
tumor
cell adhesion to endothelial cells and hyperpermeability of the endothelium, facilitating
tumor
cell invasion.
...
PMID:Nitric oxide induced by tumor cells activates tumor cell adhesion to endothelial cells and permeability of the endothelium in vitro. 934 40
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>